Get twice-weekly insights on the biggest stories shaping cardiology.
You might also like
Cardiology Pharmaceuticals September 10, 2026
Novo, Novartis, and How Two Trials Cast Doubt on CVD Biomarkers September 10, 2026
Cardiology just took back-to-back blows to two of its most promising prevention strategies. One drug for lowering lipoprotein(a) and another targeting interleukin-6 both failed in major trials, even as fresh data reaffirms just how much those factors matter.
Surgeries & Interventions September 3, 2026
A Tale of Two Studies and the Importance of Patient Selection September 3, 2026
Two recent studies are forcing an important conversation in cardiology – some of the field's most common procedures may not be as clearly beneficial as open-label data originally suggests.
Cardiology Pharmaceuticals August 31, 2026
The Full Picture Clarifies Aficamten’s Impact on nHCM August 31, 2026
We are inching closer to a treatment for nonobstructive hypertrophic cardiomyopathy after Cytokinetics presented the full results from the ACACIA-HCM trial, showing that its cardiac myosin inhibitor, MYQORZO (aficamten), meaningfully improves how nHCM patients feel and function.